The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Calidi Biotherapeutics Announces $2 Million Registered Direct Offering and Private Placement
Oct 23, 2024•over 1 year ago
Contract Type
agreement
San DiegoBiotechnologyHealth CareTherapeutics
Description
Calidi Biotherapeutics, Inc. has announced the pricing of a $2 million registered direct offering and concurrent private placement. The company will issue shares of common stock at a price of $1.00 per share in the registered direct offering, and will issue series E warrants and series F warrants in the concurrent private placement.
Company Information
Company
Calidi Biotherapeutics
Location
San Diego, California, United States
About
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
San DiegoBiotechnologyHealth CareTherapeutics